As the newest addition to incretin-based drugs, tirzepatide harbors the potential to counteract most of the pathogenetic mechanisms underpinning CKD in T2D displaying unprecedented features in terms of glucose and weight lowering, accompanied by promotion of insulin sensitivity, control of SBP, dyslipidemia, and biomarkers of inflammation and endothelial dysfunction
In stark contrast, dietary supplements marketed as "GLP-1" products are regulated under the Dietary Supplement Health and Education Act (DSHEA) of 1994, which places the burden of safety on manufacturers rather than requiring pre-market approval
Although these medications contain the same active ingredient, their approved indications and dosing differ based on formulation and strength
It is important to note that the apparent magnitude of the weight-loss effect is often influenced by baseline levels, control conditions, and follow-up windows
The severity depends on needle angle, injection depth, and individual vessel fragility